225 related articles for article (PubMed ID: 31314136)
1. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.
Juratli TA; Jones PS; Wang N; Subramanian M; Aylwin SJB; Odia Y; Rostami E; Gudjonsson O; Shaw BL; Cahill DP; Galanis E; Barker FG; Santagata S; Brastianos PK
Cancer; 2019 Sep; 125(17):2910-2914. PubMed ID: 31314136
[TBL] [Abstract][Full Text] [Related]
2. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
Brastianos PK; Shankar GM; Gill CM; Taylor-Weiner A; Nayyar N; Panka DJ; Sullivan RJ; Frederick DT; Abedalthagafi M; Jones PS; Dunn IF; Nahed BV; Romero JM; Louis DN; Getz G; Cahill DP; Santagata S; Curry WT; Barker FG
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26498373
[TBL] [Abstract][Full Text] [Related]
3. Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.
Nussbaum PE; Nussbaum LA; Torok CM; Patel PD; Yesavage TA; Nussbaum ES
J Clin Pharm Ther; 2022 Jun; 47(6):826-831. PubMed ID: 35023192
[TBL] [Abstract][Full Text] [Related]
4. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
Roque A; Odia Y
CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764
[TBL] [Abstract][Full Text] [Related]
5. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.
Rostami E; Witt Nyström P; Libard S; Wikström J; Casar-Borota O; Gudjonsson O
Acta Neurochir (Wien); 2017 Nov; 159(11):2217-2221. PubMed ID: 28918496
[TBL] [Abstract][Full Text] [Related]
6. Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor.
Aylwin SJ; Bodi I; Beaney R
Pituitary; 2016 Oct; 19(5):544-6. PubMed ID: 26115708
[No Abstract] [Full Text] [Related]
7. Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma.
Wu ZP; Wang YL; Wang LC; Liu ZY; Fan RR; Zan X; Liang RC; Yang JL; Zhou LX; Xu JG
World Neurosurg; 2023 Dec; 180():e117-e126. PubMed ID: 37683921
[TBL] [Abstract][Full Text] [Related]
8. Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review.
Yu N; Raslan OA; Lee HS; Theeler BJ; Raafat TA; Fragoso R; Shahlaie K; Aboud O
CNS Oncol; 2024 Jan; 13(1):CNS106. PubMed ID: 38348829
[TBL] [Abstract][Full Text] [Related]
9. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.
Borrill R; Cheesman E; Stivaros S; Kamaly-Asl ID; Gnanalingham K; Kilday JP
Childs Nerv Syst; 2019 Jan; 35(1):169-173. PubMed ID: 30069716
[TBL] [Abstract][Full Text] [Related]
10. BRAF plus MEK inhibition effective in papillary craniopharyngioma.
Sidaway P
Nat Rev Clin Oncol; 2023 Oct; 20(10):661. PubMed ID: 37491596
[No Abstract] [Full Text] [Related]
11. A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas.
Fujio S; Juratli TA; Arita K; Hirano H; Nagano Y; Takajo T; Yoshimoto K; Bihun IV; Kaplan AB; Nayyar N; Fink AL; Bertalan MS; Tummala SS; Curry WT; Jones PS; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
Neurosurgery; 2019 Aug; 85(2):204-210. PubMed ID: 30481321
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm.
Calvanese F; Jacquesson T; Manet R; Vasiljevic A; Lasolle H; Ducray F; Raverot G; Jouanneau E
Front Endocrinol (Lausanne); 2022; 13():882381. PubMed ID: 35757402
[TBL] [Abstract][Full Text] [Related]
13. The Medical Therapy of Craniopharyngiomas: The Way Ahead.
Alexandraki KI; Kaltsas GA; Karavitaki N; Grossman AB
J Clin Endocrinol Metab; 2019 Dec; 104(12):5751-5764. PubMed ID: 31369091
[TBL] [Abstract][Full Text] [Related]
14. [Molecularly Targeted Therapy for Craniopharyngioma].
Tanaka S; Takayanagi S; Takami H; Saito N
No Shinkei Geka; 2022 Jan; 50(1):171-178. PubMed ID: 35169097
[TBL] [Abstract][Full Text] [Related]
15. Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma.
Khaddour K; Chicoine MR; Huang J; Dahiya S; Ansstas G
J Natl Compr Canc Netw; 2020 Dec; 18(12):1590-1595. PubMed ID: 33285519
[TBL] [Abstract][Full Text] [Related]
16. Pituitary Adenoma and Papillary Craniopharyngioma: A Rare Case of Collision Tumor and Review of the Literature.
Bteich F; El Khoury L; Nohra G; Trak V; Yazbek S; Akiki M
World Neurosurg; 2020 Jul; 139():63-69. PubMed ID: 32298831
[TBL] [Abstract][Full Text] [Related]
17. BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts.
Schweizer L; Capper D; Hölsken A; Fahlbusch R; Flitsch J; Buchfelder M; Herold-Mende C; von Deimling A; Buslei R
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):733-42. PubMed ID: 25442675
[TBL] [Abstract][Full Text] [Related]
18. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
[No Abstract] [Full Text] [Related]
19. Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features.
Yue Q; Yu Y; Shi Z; Wang Y; Zhu W; Du Z; Yao Z; Chen L; Mao Y
J Neurosurg; 2018 Jul; 129(1):27-34. PubMed ID: 28984520
[TBL] [Abstract][Full Text] [Related]
20. BRAF-Directed Therapy in Metastatic Colorectal Cancer.
Korphaisarn K; Kopetz S
Cancer J; 2016; 22(3):175-8. PubMed ID: 27341594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]